Lipoprotein

Dietary supplements are big business in the United States and elsewhere, especially when it comes to products marketed to support CV health.

About 20% of the global population and one in five U.S. adults have elevated levels of lipoprotein(a), a complex form of LDL that strongly predicts risk for coronary disease and aortic valve stenosis.

High lipoprotein(a) measured during childhood was predictive of atherosclerotic CVD development during adulthood, according to an analysis of two cohorts published in Circulation.

CHICAGO — In this Healio video exclusive, Dipti Itchhaporia, MD, FACC, FESC, discusses some of the late-breaking science presented at the American Heart Association Scientific Sessions.

Lipoprotein(a) levels of 67 mg/dL or more may be indicative of similar risk for premature MI as LDL of 180 mg/dL or more in patients with familial hypercholesterolemia, researchers reported.

BOSTON — There is strong evidence for a casual association between lipoprotein(a) concentration and CV outcomes across ethnicities, and Lp(a) “should be measured at least once” in all adults to identify high CV risk, according to a speaker.

Older adults with elevated lipoprotein(a)-associated genotypes may benefit from low-dose aspirin for primary prevention of cardiovascular events, according to researchers.

Low-dose aspirin for primary prevention of CV events may benefit older adults with elevated lipoprotein(a)-associated genotypes, according to a new analysis of the ASPREE trial.

In a phase 2 trial, obicetrapib, an investigational cholesteryl ester transfer protein inhibitor, decreased LDL, non-HDL, lipoprotein(a) and apolipoprotein B and increased HDL at 8 weeks, researchers reported in Nature Medicine.

Data from a retrospective study suggest adults with very high levels of lipoprotein(a) are eight times more likely to experience aortic dissection compared with those with lower levels, independent of other CV risk factors.